Future pathways towards improving clinical safety and efficacy of immunotherapy agents in melanoma
Immuno-Oncology Insights 2020; 1(3), 157–162
Published: 8 December 2020
Paolo A Ascierto
Professor Paolo A Ascierto obtained his medical degree from the University of Naples, Italy, the institution where he subsequently earned his Board Certification in Oncology. He went on to serve consecutive positions at the National Tumour Institute “Fondazione G. Pascale”, in Naples, as a postdoctoral fellow and then as Vice Director of the Department of Clinical Immunology. Professor Ascierto is currently Director of the Department of Melanoma, Cancer Immunotherapy and Innovative therapy at that same institution. He is an active Scientific Reviewer for several international journals, including, NEJM, JCO, Lancet Oncology, and Clinical Cancer Research, as well as being the Associate Editor for Onco-Immunology of Annals of Oncology, Chief Section Editor for Combination Strategies section of Journal of Translational Medicine, Associate Editor of Journal of ImmunoTherapy of Cancer, and member of the Editorial Board fro ESMO Open. As a result of Professor Ascierto’s experience and expertise, he has been a valued invited speaker at more than 400 national and international meetings. Furthermore, he is an active member of the Italian Society of Medical Oncology (AIOM), American Society of Clinical Oncology (ASCO), European Society for Medical Oncology (ESMO), European Organization for Research and Treatment of Cancer (EORTC) and Society of Immuno Therapy of Cancer (SITC). Professor Ascierto has presided as Principal Investigator on over 120 clinical trials and he is author of more than 470 publications in peer-reviewed journals. Such journals include: The New England Journal of Medicine, The Lancet, Lancet Oncology, Journal of Clinical Oncology, Nature Medicine, JAMA Oncology, and Clinical Cancer Research, among others. Primarily, his major research interests are the genetics and proteomics of melanoma, the assessment of molecular markers for tumour progression in melanoma, management of targeted therapies for melanoma, vaccination treatments and immunotherapy of solid tumors, biochemical and immunological monitoring, and combination approaches for the cancer treatment.